Patents by Inventor Steven L. Wagner
Steven L. Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11117884Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.Type: GrantFiled: October 25, 2019Date of Patent: September 14, 2021Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Publication number: 20200055840Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.Type: ApplicationFiled: October 25, 2019Publication date: February 20, 2020Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 10472346Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.Type: GrantFiled: October 30, 2015Date of Patent: November 12, 2019Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 9938263Abstract: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.Type: GrantFiled: March 12, 2014Date of Patent: April 10, 2018Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Rudolph E. Tanzi, Steven L. Wagner, Soan Cheng, William C. Mobley
-
Publication number: 20180093967Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.Type: ApplicationFiled: October 30, 2015Publication date: April 5, 2018Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 9403815Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.Type: GrantFiled: June 24, 2011Date of Patent: August 2, 2016Assignees: The Regents of the University of California, The General Hospital CorporationInventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
-
Publication number: 20160024073Abstract: There are provided, imer alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Inventors: Rudolph E. TANZI, Steven L. WAGNER, Soan CHENG, William C. MOBLEY
-
Publication number: 20130165416Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.Type: ApplicationFiled: June 24, 2011Publication date: June 27, 2013Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
-
Publication number: 20020177120Abstract: Recombinant cells expressing fluorescence resonance energy transfer reporter polypeptides and cell-based assays for apoptosis; screening assays for identifying and selecting candidate compounds modulating apoptosis.Type: ApplicationFiled: June 4, 1999Publication date: November 28, 2002Inventors: KATHRYN J. ELLIOTT, MARIA Z. KOUNNAS, REBECCA J. DYER, BENITO MUNOZ, STEVEN L. WAGNER
-
Patent number: 5600565Abstract: Each item a system or order group carries a label having, in addition to a predetermined primary code denoting its item type, another, secondary, code representing a random identifier for that individual item. When a system or order group is to be packaged, a worker selects each item according to a list, scans its label, and physically places the item with the order group. The predetermined primary and random secondary codes are compared with those of previous items in the same order group. A complete match with the codes of another item in the same group causes the item to be rejected.Type: GrantFiled: December 22, 1994Date of Patent: February 4, 1997Assignee: International Business Machines CorporationInventors: Steven L. Wagner, Stephen E. Wheeler
-
Patent number: 5427931Abstract: Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of .beta.APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of .beta.APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of .beta.APP in CSF, down to a total concentration of the secreted forms of .beta.APP of 3.75 .mu.g/ml or lower.Type: GrantFiled: April 27, 1993Date of Patent: June 27, 1995Assignee: Then Regents of the University of CaliforniaInventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
-
Patent number: 5270165Abstract: A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample fromNOTICE OF GOVERNMENT SUPPORTThis invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.Type: GrantFiled: October 15, 1991Date of Patent: December 14, 1993Assignee: The Reagents of the University of CaliforniaInventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
-
Patent number: 5213962Abstract: Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed.Type: GrantFiled: July 30, 1992Date of Patent: May 25, 1993Assignee: The Regents of the University of CaliforniaInventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
-
Patent number: 5134076Abstract: Monoclonal antibodies having a specificity for protease nexin-1 are described. Preferably an antibody has specificity to the reactive protease-binding site. The antibody is used in the affinity purification of PN-1 to produce large quantities of substantially pure PN-1, free of other biologically active molecules. Over a 2000-fold purification of a crude preparation of PN-1 may be obtained. The affinity-purified PN-1 is suitable for use in pharmacological preparations used in the treatment of neurological disease associated with serine protease-mediated inhibition of regenerative processes.Type: GrantFiled: September 27, 1988Date of Patent: July 28, 1992Assignee: The Regents of the University of CaliforniaInventors: Dennis D. Cunningham, Steven L. Wagner, William E. Van Nostrand